慢性丙型肝炎清除病毒后疾病进展风险评估

王琴; 罗碧芬; 魏来

doi:10.3969/j.issn.1001-5256.2018.02.001

慢性丙型肝炎清除病毒后疾病进展风险评估

DOI: 10.3969/j.issn.1001-5256.2018.02.001

北京大学人民医院北京大学肝病研究所

详细信息

中图分类号: R512.63
计量
- 文章访问数: 2048
- HTML全文浏览量: 17
- PDF下载量: 515
- 被引次数: 0
出版历程
- 收稿日期: 2018-01-17
- 出版日期: 2018-02-20

A risk assessment of disease progression after virus elimination with chronic hepatitis C

People's Hospital, Peking University, Peking University Hepatology Institute

摘要

摘要: 综合世界各地多个基于干扰素α和聚乙二醇干扰素α的临床研究,慢性丙型肝炎患者进行抗病毒治疗并取得丙型肝炎病毒清除后能有效缓解甚至逆转肝纤维化,降低肝硬化失代偿和相关并发症发生率以及肝细胞癌的发生,提高生存率。
- 肝炎,丙型,慢性 /
- 肝硬化 /
- 癌,肝细胞 /
- 干扰素α /
- 危险因素 /
- 述评
Abstract: With reference to various clinical studies on interferon-α and pegylated interferon-α around the world, patients with chronic hepatitis C who receive antiviral therapy and achieve the elimination of hepatitis C virus may have significant relief or even reversion of liver fibrosis, as well as reductions in the incidence rates of decompensated liver cirrhosis, related complications, and hepatocellular carcinoma and an increase in survival rate.
- hepatitis C, chronic /
- liver cirrhosis /
- carcinoma, hepatocellular /
- interferon-alpha /
- risk factors /
- editorial

HTML全文

参考文献(14)

[1]SHIRATORI Y, IMAZEKI F, MORIYAMA M, et al.Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy[J].Ann Intern Med, 2000, 132 (7) :517-524.

[2]YOSHIDA H, SHIRATORI Y, MORIYAMA M, et al.Interferon therapy reduces the risk for hepatocellular carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan.IHIT Study Group.Inhibition of Hepatocarcinogenesis by Interferon Therapy[J].Ann Intern Med, 1999, 131 (3) :1741-1781.

[3]SHIRATORI Y, SHIINA S, TERATANI T, et al.Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus[J].Ann Intern Med, 2003, 138 (4) :299-306.

[4]YOSHIDA H, ARAKAWA Y, SATA M, et al.Interferon therapy prolonged life expectancy among chronic hepatitis C patients[J].Gastroenterology, 2002, 123 (2) :483-491.

[5]YU ML, CHUANG WL.Treatment of chronic hepatitis C in Asia:when east meets west[J].J Gastroenterol Hepatol, 2009, 24 (3) :336-345.

[6]PAWLOTSKY JM, FELD JJ, ZEUZEM S, et al.From non-A, non-B hepatitis to hepatitis C virus cure[J].J Hepatol, 2015, 62 (1 Suppl) :s87-s99.

[7]MORGAN TR, GHANY MG, KIM HY, et al.Outcome of sustained virological responders with histologically advanced chronic hepatitis C[J].Hepatology, 2010, 52 (3) :833-844.

[8]LI DK, CHUNG RT.Impact of hepatitis C virus eradication on hepatocellular carcinogenesis[J].Cancer, 2015, 121 (17) :2874-2882.

[9]CHANG KC, HUNG CH, LU SN, et al.A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy[J].J Antimicrob Chemother, 2012, 67 (11) :2766-2772.

[10]MAURO E, CRESPO G, MONTIRONI C, et al.Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after SVR in recurrent hepatitis C[J].Hepatology, 2017.[Epub ahead of print]

[11]WANG JH, YEN YH, YAO CC, et al.Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy[J].Liver Int, 2016, 36 (12) :1793-1799.

[12]XING J, SPRADLING PR, MOORMAN AC, et al.Chronic Hepatitis Cohort Study (CHe CS) Investigators.A point system to forecast hepatocellular carcinoma risk before and after treatment among persons with chronic hepatitis C[J].Dig Dis Sci, 2017, 62 (11) :3221-3234.

[13]UMEHARA Y, HAGIWARA S, NISHIDA N, et al.Hepatocarcinogenesis is associated with serum albumin levels after sustained virological responses with interferon-based therapy in patients with hepatitis C[J].Dig Dis, 2017, 35 (6) :548-555.

[14]NAHON P, BOURCIER V, LAYESE R, et al.Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications[J].Gastroenterology, 2017, 152 (1) :142-156.e2.

施引文献

资源附件(0)

访问统计